Abstract: The present disclosure provides, among other things, compositions and methods useful for inhibiting biofilm-forming bacteria. For example, the compositions and methods described herein can be used to inhibit the proliferation, viability, and/or biofilm-forming activity, of biofilm-forming bacteria.

Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.

Abstract: A pharmaceutical preparation, comprising: A) A plurality of particles, each particle comprising: 1) a core comprising at least one agent that increases oxygen tension and/or redox potential and/or pH in the colon of a subject following administration to the subject, and 2) an enteric coating encasing the core; and B) a capsule or sachet encasing the plurality of particles. Methods of weight management for a subject, comprising administering the pharmaceutical preparation to a subject in need thereof.

Abstract: A cookie that provides a prebiotic effect and/or a probiotic effect to a consumer is described. The cookie fails to contain refined sugars, synthetic vitamins, genetically modified organisms (GMOs), artificial sweeteners, and artificial preservatives. The cookie comprises at least two baked food compositions formed into a biscuit. Each of the at least two baked food compositions contains a polyphenol, a resistant starch, and a prebiotic soluble fiber. A crème filing is sandwiched between the at least two baked food compositions. The crème filing comprises a resistant starch, a nut butter, a vegetable fat, and spores of a probiotic bacterium. Consumption of the cookie increases Lactobacillus bulgaricus and butyrate in the consumer.

Abstract: The present invention relates to propanediol monoacetate mononitrate as well as the use thereof as antimicrobial agent, in particular for cosmetic applications.

Abstract: A topical composition comprising a Polymer, a high molecular weight hyaluronic acid (HWM HA) and/or its salt, a low molecular weight hyaluronic acid (LWM HA) and/or its salt, and a polyamino acid and/or its salt; and water and a method for identifying a test polymer that forms a micro-mesh structure when combined with such ingredients.

Abstract: A hair care composition directed to from about 14% to about 40% of one or more surfactants; from about 0.1% to 10% of one or more surfactant soluble antidandruff agents; wherein when the hair care composition is diluted to 1.3% surfactant concentration has a ratio of surfactant diffusion coefficient to soluble agent diffusion coefficient less than 0.6 or greater than 1.4.

Abstract: A product includes a metallogel material having metal ions dispersed in an assembly having an organic compound. A method includes combining a metal salt, an organic compound precursor, and a glyme for forming a metallogel material having metal ions dispersed in an assembly having an organic compound.

Abstract: The present invention provides for pharmaceutical preparations, devices, systems and methods for the treatment of otic diseases and conditions. In various embodiments, the preparations, devices, systems and methods enable sustained drug release for the treatment or prevention of hearing loss, infections, and other pathological conditions of cochlea and inner ear.

Abstract: The present invention involves a novel aqueous iron composition. The aqueous iron composition includes iron sucrose and bicarbonate. The aqueous iron composition of the invention exhibits enhanced renal protective effects relative to conventional iron sucrose compositions.

Abstract: To provide a bioimplant capable of controlling a rate of an antibacterial agent and an antibiotic to be eluted from the coating film. An evanescent coating film made of a calcium phosphate-based material having crystallinity of 10% to 90% is formed at a predetermined area of the bioimplant and an antibacterial agent or an antibiotic is contained in the coating film to suppress adhesion of bacteria.

Abstract: In some embodiments, the disclosure provides a method of making a sterile lacosamide composition, the method comprising; (a) obtaining a composition comprising (i) about 5 mg/mL to about 20 mg/mL lacosamide, (ii) about 5 mg/mL to about 12 mg/mL sodium chloride, and (iii) water, (b) placing the composition of (a) into a glass vial, wherein the glass vial has an ammonium sulfate coating, (c) sealing the composition inside the glass vial; and (d) autoclaving the sealed glass vial of (c) at 121° C. at 15 lbs pressure for 15 minutes, wherein the pH of the composition in (d) is substantially the same as the pH of the composition after (a), and wherein the composition of (d) comprises less than about 0.2% (wt/wt) of Impurity A, Impurity B, Impurity C, Impurity D, Impurity E or Impurity F.

Abstract: The present disclosure generally relates to a process for manufacturing a dry powder composition, particularly to a co-sprayed colistin and meropenem dry powder inhaler for the treatment of various bacterial infections. Methods of use and composition matters are within the scope of this disclosure.

Abstract: The invention relates to a antimicrobial and cleansing composition consisting of a. a polymeric biguanide, and b. a metal ion chelating agent, and g. a solvent, wherein the ratio of a:b is between 0.75:2.25 and 1.25:2.25, or about 1:2, and optionally one or more of the following ingredients; c. a quaternary ammonium salt, d. at least one surfactant, e. a humectant and f. a gelling agent. The invention further relates to said composition for use in a treatment, prevention or reduction of a disease, disorder or condition related to microbials, or treatment, prevention or reduction of infection, or inflammation, or infected wounds, or inflamed wounds, or treatment, prevention or reduction of biofilms, or removal of necrotic tissue. A liquid flow system may be used for administration of the composition.

Abstract: A simple, self-propelling particle system is disclosed that can deliver a cargo through flowing aqueous solutions. This disclosure provides a non-aqueous composition comprising: (i) particles formed of a carbonate salt and having an average diameter of about 100 ?m or less; and (ii) an acid in solid form. The particles may be associated with a cargo molecule or particle. In mouse models of severe hemorrhage, the propelled particles are able to deliver a procoagulant enzyme and halt bleeding.

Abstract: Disclosed is a cosmetic composition comprising (i) 1 to 30 wt % of a non-hydrocarbon emollient; and (ii) 2 to 60 wt % of a blend of silicone elastomer gel of the Formula (I) and solvent; wherein the solvent for the silicone elastomer gel is selected from cyclic or linear polydimethylsiloxanes; wherein the w/w ratio of the amount of the non-hydrocarbon emollient to the combined amounts of the silicone elastomer gel and said solvent is from 1:50 to 1:1 and where the amount of the non-hydrocarbon emollient is less than the amount of the silicone elastomer gel; and wherein the composition comprises less than 2 wt % capric caprylic triglycerides and less than 5 wt % crosslinked elastomeric silicone polyether, wherein said non-hydrocarbon emollient is an alkenyl or alkyl ester of a C10-20 fatty acid, an ether-ester, a polyhydric alcohol ester, a wax ester, a mono-, di- or triglyceride, a sterol ester, a fatty alcohol, a fatty acid, lanolin or its derivative, wax ester, a phospholipid, beeswax or a sterol.

Abstract: A method of oral delivery of phospholipid/inulin compositions comprising capsules, tablets, chewable wafers or powdered material in a liquid carrier in quantities effective for treating pain from overactive neurons. The phospholipid/inulin compositions were also shown to be effective in reducing depression and intestinal malfunctions including, but not limited to, diarrhea and constipation, and improving sleep pattern. The compositions further including effective amounts of caffeine also reduces fatigue and enhances alertness and focus.

Abstract: According to aspects of the present invention, a peptide with any one sequence of SEQ ID NOS:1 to 3 exhibits high selective binding affinity to a target and the microcapsule has superior physicochemical stability. Therefore, the cosmetic composition containing the microcapsule linked to the peptide manifests high delivery efficiency of an active ingredient included in the capsule to target cells, thereby exhibiting superior skin-condition improvement effects.

Abstract: The present invention relates to a lozenge composition for controlled release of cannabinoids comprising; i) a master granule component comprising one or more solid particles and one or more cannabinoids reversibly associated with the one or more solid particles; and ii) an extragranular component blended with the master granule component comprising one or more extragranular sugar alcohols.

Abstract: The present invention discloses an organic skin moisturizer, which extends and improves the skin cells. The composition is dermatologically acceptable and is capable of moisturizing skin for at least twelve hours after topical application to skin even after multiple washings of the skin.